COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

DOI
Publisher DOI
PubMed ID
34725454
Abstract
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
Date Issued
2021-12
Publication Type
Article
Subject(s)
Language(s)
en
Author(s)
Chatzikonstantinou, Thomas
Kapetanakis, Anargyros
Scarfò, Lydia
Karakatsoulis, Georgios
Allsup, David
Cabrero, Alejandro Alonso
Antic, Darko
Baile, Mónica
Baliakas, Panagiotis
Bron, Dominique
Capasso, Antonella
Chatzileontiadou, Sofia
Cordoba, Raul
Correa, Juan-Gonzalo
Cuéllar-García, Carolina
De Paoli, Lorenzo
De Paolis, Maria Rosaria
Del Poeta, Giovanni
Demosthenous, Christos
Dimou, Maria
Donaldson, David
Doubek, Michael
Efstathopoulou, Maria
Eichhorst, Barbara
El-Ashwah, Shaimaa
Enrico, Alicia
Espinet, Blanca
Farina, Lucia
Ferrari, Angela
Foglietta, Myriam
Frederiksen, Henrik
Fürstenau, Moritz
García-Marco, José A
García-Serra, Rocío
Gentile, Massimo
Gimeno, Eva
Glenthøj, Andreas
Gomes da Silva, Maria
Gutwein, Odit
Hakobyan, Yervand K
Herishanu, Yair
Hernández-Rivas, José Ángel
Herold, Tobias
Innocenti, Idanna
Itchaki, Gilad
Jaksic, Ozren
Janssens, Ann
Kalashnikova, Оlga B
Kalicińska, Elżbieta
Karlsson, Linda Katharina
Kater, Arnon P
Kersting, Sabina
Labrador, Jorge
Lad, Deepesh
Laurenti, Luca
Levin, Mark-David
Lista, Enrico
Lopez-Garcia, Alberto
Malerba, Lara
Marasca, Roberto
Marchetti, Monia
Marquet, Juan
Mattsson, Mattias
Mauro, Francesca R
Milosevic, Ivana
Mirás, Fatima
Morawska, Marta
Motta, Marina
Munir, Talha
Murru, Roberta
Niemann, Carsten U
Rodrigues, Raquel Nunes
Olivieri, Jacopo
Orsucci, Lorella
Papaioannou, Maria
Pavlovsky, Miguel Arturo
Piskunova, Inga
Popov, Viola Maria
Quaglia, Francesca Maria
Quaresmini, Giulia
Qvist, Kristian
Reda, Gianluigi
Rigolin, Gian Matteo
Ruchlemer, Rosa
Saghumyan, Gevorg
Shrestha, Amit
Šimkovič, Martin
Špaček, Martin
Sportoletti, Paolo
Stanca, Oana
Stavroyianni, Niki
Tadmor, Tamar
Te Raa, Doreen
Tonino, Sanne H
Trentin, Livio
Van Der Spek, Ellen
van Gelder, Michel
van Kampen, Roel
Varettoni, Marzia
Visentin, Andrea
Vitale, Candida
Wasik-Szczepanek, Ewa
Wróbel, Tomasz
San Segundo, Lucrecia Yáñez
Yassin, Mohamed
Coscia, Marta
Rambaldi, Alessandro
Montserrat, Emili
Foà, Robin
Cuneo, Antonio
Stamatopoulos, Kostas
Ghia, Paolo
Additional Credits
Journal
Leukemia
Publisher
Springer Nature
ISSN
0887-6924
Access(Rights)
open.access
Show full item